Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy.

RECENT FINDINGS: As our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old question on the best conditioning regimen to be used in this setting, while a recent randomized controlled study fixed the optimal anti-thymocyte globulin dose in unrelated donor HSCT. HSCT, the oldest immunotherapy used in clinical practice, still represents the gold standard consolidation treatment for a number of pediatric patients with high-risk/relapsed ALL. New immunotherapies hold the promise of further improving outcomes in this setting.

Original languageEnglish
JournalCurrent Hematologic Malignancy Reports
DOIs
Publication statusE-pub ahead of print - Feb 26 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Immunotherapy
Unrelated Donors
Antilymphocyte Serum
Tissue Donors
Therapeutics
Conditioning (Psychology)

Cite this

@article{b87f95623a0048dd96650b07392daee8,
title = "Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia",
abstract = "PURPOSE OF REVIEW: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy.RECENT FINDINGS: As our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old question on the best conditioning regimen to be used in this setting, while a recent randomized controlled study fixed the optimal anti-thymocyte globulin dose in unrelated donor HSCT. HSCT, the oldest immunotherapy used in clinical practice, still represents the gold standard consolidation treatment for a number of pediatric patients with high-risk/relapsed ALL. New immunotherapies hold the promise of further improving outcomes in this setting.",
author = "Pietro Merli and Mattia Algeri and {Del Bufalo}, Francesca and Franco Locatelli",
year = "2019",
month = "2",
day = "26",
doi = "10.1007/s11899-019-00502-2",
language = "English",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

AU - Merli, Pietro

AU - Algeri, Mattia

AU - Del Bufalo, Francesca

AU - Locatelli, Franco

PY - 2019/2/26

Y1 - 2019/2/26

N2 - PURPOSE OF REVIEW: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy.RECENT FINDINGS: As our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old question on the best conditioning regimen to be used in this setting, while a recent randomized controlled study fixed the optimal anti-thymocyte globulin dose in unrelated donor HSCT. HSCT, the oldest immunotherapy used in clinical practice, still represents the gold standard consolidation treatment for a number of pediatric patients with high-risk/relapsed ALL. New immunotherapies hold the promise of further improving outcomes in this setting.

AB - PURPOSE OF REVIEW: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy.RECENT FINDINGS: As our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old question on the best conditioning regimen to be used in this setting, while a recent randomized controlled study fixed the optimal anti-thymocyte globulin dose in unrelated donor HSCT. HSCT, the oldest immunotherapy used in clinical practice, still represents the gold standard consolidation treatment for a number of pediatric patients with high-risk/relapsed ALL. New immunotherapies hold the promise of further improving outcomes in this setting.

U2 - 10.1007/s11899-019-00502-2

DO - 10.1007/s11899-019-00502-2

M3 - Review article

C2 - 30806963

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -